Literature DB >> 35244678

Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.

Lauren C Peres1, Christelle Colin-Leitzinger1, Sweta Sinha1, Jeffrey R Marks2, Jose R Conejo-Garcia3, Anthony J Alberg4, Elisa V Bandera5, Andrew Berchuck6, Melissa L Bondy7, Brock C Christensen8,9,10, Michele L Cote11,12, Jennifer Anne Doherty13,14, Patricia G Moorman15, Edward S Peters16, Carlos Moran Segura17, Jonathan V Nguyen17, Ann G Schwartz11,12, Paul D Terry18, Christopher M Wilson19, Brooke L Fridley19, Joellen M Schildkraut20.   

Abstract

BACKGROUND: Tumor-infiltrating lymphocytes (TIL) confer a survival benefit among patients with ovarian cancer; however, little work has been conducted in racially diverse cohorts.
METHODS: The current study investigated racial differences in the tumor immune landscape and survival of age- and stage-matched non-Hispanic Black and non-Hispanic White women with high-grade serous ovarian carcinoma (HGSOC) enrolled in two population-based studies (n = 121 in each racial group). We measured TILs (CD3+), cytotoxic T cells (CD3+CD8+), regulatory T cells (CD3+FoxP3+), myeloid cells (CD11b+), and neutrophils (CD11b+CD15+) via multiplex immunofluorescence. Multivariable Cox proportional hazard regression was used to estimate the association between immune cell abundance and survival overall and by race.
RESULTS: Overall, higher levels of TILs, cytotoxic T cells, myeloid cells, and neutrophils were associated with better survival in the intratumoral and peritumoral region, irrespective of tissue compartment (tumor, stroma). Improved survival was noted for T-regulatory cells in the peritumoral region and in the stroma of the intratumoral region, but no association for intratumoral T-regulatory cells. Despite similar abundance of immune cells across racial groups, associations with survival among non-Hispanic White women were consistent with the overall findings, but among non-Hispanic Black women, most associations were attenuated and not statistically significant.
CONCLUSIONS: Our results add to the existing evidence that a robust immune infiltrate confers a survival advantage among women with HGSOC; however, non-Hispanic Black women may not experience the same survival benefit as non-Hispanic White women with HGSOC. IMPACT: This study contributes to our understanding of the immunoepidemiology of HGSOC in diverse populations. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35244678      PMCID: PMC9081269          DOI: 10.1158/1055-9965.EPI-21-1334

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  47 in total

Review 1.  Foxp3 expression in T regulatory cells and other cell lineages.

Authors:  Christel Devaud; Phillip K Darcy; Michael H Kershaw
Journal:  Cancer Immunol Immunother       Date:  2014-07-26       Impact factor: 6.968

2.  Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.

Authors:  Charlotte S Lo; Sanaz Sanii; David R Kroeger; Katy Milne; Aline Talhouk; Derek S Chiu; Kurosh Rahimi; Patricia A Shaw; Blaise A Clarke; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2016-09-06       Impact factor: 12.531

3.  Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.

Authors:  Xia Yuan; Jing Zhang; Dan Li; Ye Mao; Fei Mo; Wei Du; Xuelei Ma
Journal:  Gynecol Oncol       Date:  2017-07-08       Impact factor: 5.482

4.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

Review 5.  The Immunoscore: Colon Cancer and Beyond.

Authors:  Helen K Angell; Daniela Bruni; J Carl Barrett; Ronald Herbst; Jérôme Galon
Journal:  Clin Cancer Res       Date:  2019-08-14       Impact factor: 12.531

6.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 7.  Top 10 Challenges in Cancer Immunotherapy.

Authors:  Priti S Hegde; Daniel S Chen
Journal:  Immunity       Date:  2020-01-14       Impact factor: 31.745

Review 8.  Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis.

Authors:  Meixiao Shen; Pingping Hu; Frede Donskov; Guanghui Wang; Qi Liu; Jiajun Du
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.

Authors:  Ewa Przybytkowski; Thomas Davis; Abdelrahman Hosny; Julia Eismann; Ursula A Matulonis; Gerburg M Wulf; Sheida Nabavi
Journal:  BMC Cancer       Date:  2020-03-12       Impact factor: 4.430

10.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.